Published in Blood Weekly, April 25th, 2002
Dynavax said that the objective of the study is to produce data on the compound's pharmacokinetics and on biological response markers and that it plans to use the data to select an appropriate dosage for further development of the compound in a blinded, phase II placebo-controlled...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.